SuPreme Study: a protocol to study the neuroprotective potential of sulfate among very/extremely preterm infants

Author:

Hurrion Elizabeth MORCID,Badawi Nadia,Boyd Roslyn N,Morgan CatherineORCID,Gibbons Kristen,Hennig Stefanie,Koorts Pieter,Chauhan Manbir,Bowling Francis,Flenady Vicki,Kumar SaileshORCID,Dawson Paul AORCID

Abstract

IntroductionAntenatal maternal magnesium sulfate (MgSO4) administration is a proven efficacious neuroprotective treatment reducing the risk of cerebral palsy (CP) among infants born preterm. Identification of the neuroprotective component with target plasma concentrations could lead to neonatal treatment with greater efficacy and accessibility.Methods and analysisThis is a prospective observational cohort study, in three tertiary Australian centres. Participants are preterm infants, irrespective of antenatal MgSO4exposure, born in 2013–2020 at 24+0to 31+6weeks gestation, and followed up to 2 years corrected age (CA) (to September 2023). 1595 participants are required (allowing for 17% deaths/loss to follow-up) to detect a clinically significant reduction (30% relative risk reduction) in CP when sulfate concentration at 7 days of age is 1 SD above the mean.A blood sample is collected on day 7 of age for plasma sulfate and magnesium measurement. In a subset of participants multiple blood and urine samples are collected for pharmacokinetic studies, between days 1–28, and in a further subset mother/infant blood is screened for genetic variants of sulfate transporter genes.The primary outcome is CP. Surviving infants are assessed for high risk of CP at 12–14 weeks CA according to Prechtl’s Method to assess General Movements. Follow-up at 2 years CA includes assessments for CP, cognitive, language and motor development, and social/behavioural difficulties.Multivariate analyses will examine the association between day 7 plasma sulfate/magnesium concentrations with adverse neurodevelopmental outcomes. A population pharmacokinetic model for sulfate in the preterm infant will be created using non-linear mixed-effects modelling.Ethics and disseminationThe study has been approved by Mater Misericordiae Ltd Human Research Ethics Committee (HREC/14/MHS/188). Results will be disseminated in peer-reviewed journal publications, and provided to the funding bodies. Using consumer input, a summary will be prepared for participants and consumer groups.

Funder

Cerebral Palsy Alliance Research Foundation

Mater Foundation

NHMRC

Publisher

BMJ

Subject

General Medicine

Reference57 articles.

1. March of Dimes, PMNCH, Save the Children, WHO . Born Too Soon: The Global Action Report on Preterm Birth. Geneva: World Health Organization, 2012.

2. Early and long-term outcome of infants born extremely preterm

3. The life course consequences of very Preterm birth;Wolke;Annu Rev Dev Psychol,2019

4. Hodek J-M , von der Schulenburg J-M , Mittendorf T . Measuring economic consequences of Preterm birth - methodological recommendations for the evaluation of personal burden on children and their Caregivers. Health Econ Rev 2011;1:6. doi:10.1186/2191-1991-1-6

5. Australian Cerebral Palsy Register Group . Report of the Australian Cerebral Palsy Register, Birth Years 1993 – 2003. Sydney: CP Register, 2009.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3